Literature DB >> 9778266

Neonatal cytokines and coagulation factors in children with cerebral palsy.

K B Nelson1, J M Dambrosia, J K Grether, T M Phillips.   

Abstract

We explored the association of inflammatory mediators and markers of autoimmune and coagulation disorders with cerebral palsy (CP), examining 53 analytes in dried neonatal blood of 31 children with spastic CP, most born at term, and 65 control children. Ultramicroanalysis was performed by recycling immunoaffinity chromatography coupled with laser-enhanced fluorescence and chemiluminescence detection. Reactive antibodies to lupus anticoagulant, anticardiolipin, antithrombin III, and the translational product of the factor V Leiden mutation were isolated by recycling immunoaffinity chromatography and measured by capillary electrophoresis with chemiluminescence-enhanced immunoassay. Higher concentrations of interleukins (ILs) 1, 8, 9, tumor necrosis factor-alpha, and RANTES were observed in these children with CP than in any control child. There were also substantial elevations of IL-6, 11, 13, and other chemokines and colony-stimulating factors in children with CP. Antiphospholipid antibody was present in a titer of 1:100 or greater in 4 children with CP and no control child. Using cuts empirically chosen by recursive partitioning, we found higher concentrations of antibody to antithrombin III, to a translational product of factor V Leiden mutation, and to proteins C and S in children with CP than in controls. We conclude that inflammation and these coagulation abnormalities, which have interacting pathways, are important in the etiology of CP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778266     DOI: 10.1002/ana.410440413

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  79 in total

1.  Cranial ultrasound abnormalities in full term infants in a postnatal ward: outcome at 12 and 18 months.

Authors:  L Haataja; E Mercuri; F Cowan; L Dubowitz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

Review 2.  Recent advances: obstetrics.

Authors:  J M Roberts
Journal:  BMJ       Date:  2000-07-01

Review 3.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?

Authors:  P V Mohan; W Tarnow-Mordi; B Stenson; P Brocklehurst; K Haque; V Cavendish; A Cust
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

Review 4.  Postnatal steroid treatment and brain development.

Authors:  O Baud
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

5.  A mouse model of term chorioamnionitis: unraveling causes of adverse neurological outcomes.

Authors:  Irina Burd; Amy Brown; Juan M Gonzalez; Jinghua Chai; Michal A Elovitz
Journal:  Reprod Sci       Date:  2011-03-18       Impact factor: 3.060

6.  The relation between pre-eclampsia at term and neonatal encephalopathy.

Authors:  L Impey; C Greenwood; O Sheil; K MacQuillan; M Reynolds; C Redman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

Review 7.  Inflammatory Biomarkers of Birth Asphyxia.

Authors:  Lina F Chalak
Journal:  Clin Perinatol       Date:  2016-09       Impact factor: 3.430

Review 8.  Systemic prenatal insults disrupt telencephalon development: implications for potential interventions.

Authors:  Shenandoah Robinson
Journal:  Epilepsy Behav       Date:  2005-08-02       Impact factor: 2.937

Review 9.  The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants.

Authors:  M A Crawford; I Golfetto; K Ghebremeskel; Y Min; T Moodley; L Poston; A Phylactos; S Cunnane; W Schmidt
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

Review 10.  Molecular mechanisms involved in injury to the preterm brain.

Authors:  Angela M Kaindl; Géraldine Favrais; Pierre Gressens
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.